

I hereby certify that this correspondence is being  
facsimile transmitted to the United States Patent  
and Trademark Office on the date shown below:

January 18, 2007

David Saliwanchik  
David R. Saliwanchik, Patent Attorney

RESPONSE UNDER 37 CFR 1.111

Examining Group 1617

Patent Application

Docket No. GJE-6758

Serial No. 10/519,594

RECEIVED

CENTRAL FAX CENTER

JAN 18 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Layla Soroush  
Art Unit : 1617  
Applicant : David Cavalla, Robert William Gristwood  
Serial No. : 10/519,594  
Conf. No. : 2624  
Filed : December 28, 2004  
For : 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-D)  
Pyrimidine in the Treatment of Functional Bowel Disorder

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA. 22313-1450

RESPONSE UNDER 37 CFR 1.111

Sir:

A Petition and Fee for a three-month Extension of Time accompany this paper.

In response to the Office Action dated July 27, 2006, the following remarks are respectfully  
presented.

Remarks/Arguments follow the amendment sections of this paper.

J:\gjc\6758\pto\Amend.doc\DNB\la